Neil P. Shah, Dong-Wook Kim, Hagop Kantarjian, Philippe Rousselot, Pedro Enrique Dorlhiac Llacer, Alicia Enrico, Jorge Vela-Ojeda, Richard T. Silver, Hanna Jean Khoury, Martin C. Müller, Alexandre Lambert, Yousif Matloub, Andreas Hochhaus. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. haematol [Internet]. 2010Feb.1 [cited 2021Sep.23];95(2):232-40. Available from: https://haematologica.org/article/view/5493